Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
LadRx Corp
LADX
Healthcare
Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an...
organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCQB:LADX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 27, 2013 7:26pm
CytRx Corp. (CYTR) Featured on Forbes.com for Aldoxorubicin’
CytRx Corp. (CYTR) Featured on Forbes.com for Aldoxorubicin’s Potential as Treatment for Brain Cancer In a recent review published on Forbes.com, contributor Tom Meyer highlights
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 26, 2013 5:24pm
CytRx Corp. (CYTR) Featured in Bullish Seeking Alpha Article
CytRx Corp. (CYTR) Featured in Bullish Seeking Alpha Article CytRx, a biopharm research and development company specializing in the development of drug candidates for the field of oncology, was
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 18, 2013 5:53pm
Wall Street Cheat Sheet Contributor Corrects Allegedly “Inac
Wall Street Cheat Sheet Contributor Corrects Allegedly “Inaccurate” CytRx Corp. (CYTR) Article Shares of biotech company CytRx saw gains of 150 percent from December 9
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 13, 2013 7:17pm
CytRx Corp. (CYTR) Price Rally, Potential Mirrors Pharmacycl
CytRx Corp. (CYTR) Price Rally, Potential Mirrors Pharmacyclics (PCYC) Performance It’s quite a catching opener, especially if you’re an investor with an
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 11, 2013 7:03pm
CytRx, Inc. (CYTR) Reports Statistically Significant Results
CytRx, Inc. (CYTR) Reports Statistically Significant Results from Aldoxorubicin Phase 2b CytRx, an biopharmaceutical innovator of oncology treatments, today announced extremely promising results in
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 11, 2013 7:00pm
CytRx, Inc. (CYTR) Hosting Conference Call at 10:30 AM EST T
CytRx, Inc. (CYTR) Hosting Conference Call at 10:30 AM EST Today for Global Phase 2b Clinical Trial Data of Aldoxorubicin CytRx, a biopharmaceutical research and development company that specializes
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 05, 2013 6:30pm
CytRx Corp. (CYTR) Ready to Join Broader Rally, Says Wall St
CytRx Corp. (CYTR) Ready to Join Broader Rally, Says Wall Street Cheat Sheet Writer CytRx was recently featured in an article by author Tom Meyer, who suggests the biopharm company is on the verge
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Dec 04, 2013 8:06pm
CytRx Corp. (CYTR) Presenting at Oppenheimer 24th Annual Hea
CytRx Corp. (CYTR) Presenting at Oppenheimer 24th Annual Healthcare Conference; Receives Positive Mention on StreetInsider.com CytRx, a biopharmaceutical research and development company specializing
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 27, 2013 10:57am
CytRx Corp. (CYTR) Scheduled to Present at the LD Micro’s Ma
CytRx Corp. (CYTR) Scheduled to Present at the LD Micro’s Main Event Conference in Los Angeles CytRx Corp., a biopharmaceutical research and development company specializing in
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 26, 2013 3:17pm
CytRx Corp. (CYTR) Scheduled to Present at the LD Micro’s Ma
CytRx Corp. (CYTR) Scheduled to Present at the LD Micro’s Main Event Conference in Los Angeles CytRx Corp., a biopharmaceutical research and development company specializing in
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 25, 2013 9:43am
Highly regarded neurosurgeon now owns 8.3% of CYTR
Gene Z. Salkind, M.D., an award-winning neurosurgeon and member of the Congress of Neurological Surgeons, filed a 13G with the SEC showing that he owns just shy of 3.5M shares or 8.3% of CytRx, a
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 20, 2013 8:55pm
CytRx Corp. (CYTR) Demonstrating Aldoxorubicin’s Potential a
CytRx Corp. (CYTR) Demonstrating Aldoxorubicin’s Potential as Viable Cancer Treatment, Says Trading Coach CytRx, a biopharm research and development company specializing in
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 20, 2013 8:47pm
CytRx Corp. (CYTR) Begins Phase 2 Clinical Trial with Aldoxo
CytRx Corp. (CYTR) Begins Phase 2 Clinical Trial with Aldoxorubicin in Patients with Certain Brain Cancer CytRx Corp., a biopharmaceutical research and development company specializing in oncology
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 13, 2013 5:29pm
Exclusive Interview with CytRx Corp. (CYTR) Company Leaders
Exclusive Interview with CytRx Corp. (CYTR) Company Leaders Released by MissionIR A recent exclusive interview with CytRx Corp. President and CEO Steven Kriegsman, along with company Vice President of
...more
(0)
•••
MissionIR
X
View Profile
View Bullboard History
Post by
MissionIR
on Nov 07, 2013 4:17pm
CytRx Corp. (CYTR) Management Joins MissionIR in Exclusive I
CytRx Corp. (CYTR) Management Joins MissionIR in Exclusive Interview MissionIR today released its interview with CytRx President and Chief Executive Officer Steven Kriegsman, as well as the company
...more
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Nanalysis Scientific Corp. Announces First Quarter 2024 Results
This Small-Cap Gold Stock Jumped Almost 50% on Friday